BioRestorative Therapies, Inc. BRTX
Managed Health Care · data as of November 13, 2026
BioRestorative Therapies, Inc. (BRTX) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to March 31, 2026 it had revenue of $357870 and net income of -$11M, a net margin of -3089.6%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 36% a year, a 5-year average ROIC of -803%.
About BioRestorative Therapies
BioRestorative Therapies is listed in the US and classified in managed health care. Revenue went from $415996 in 2014 to $359700 in 2025, a decline of about 1.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 149% over three years (dilution for shareholders). It spends 2806% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $357870 | $359700 | $401000 | $145800 | $119800 | $46000 | $77000 | $130000 | $111000 | $81000 | $36355 |
| Net income | -$11M | -$14M | -$9M | -$10M | -$13M | -$44M | -$11M | -$15M | -$13M | -$9M | -$9M |
| Free cash flow | -$12M | -$11M | -$8M | -$7M | -$6M | -$3M | — | -$7M | -$5M | -$4M | -$5M |
| EPS (diluted) | $-1.07 | $-1.58 | $-1.16 | $-2.47 | $-3.65 | $-37.30 | $-28.56 | $-2640.00 | $-6559.99 | $-6959.99 | $-8399.99 |
| Net margin | -3089.6% | -3959.4% | -2239.2% | -7145.2% | -11037.0% | -96311.5% | -14639.9% | -11267.6% | -11277.3% | -11660.1% | -23755.4% |
| ROIC | — | -3465.0% | -107.0% | -118.3% | -141.5% | -181.5% | -62.8% | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $300.00, 20034% above the current price; targets range from $300.00 to $300.00; the consensus rating is “none”; expected EPS is $-13.20 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does BioRestorative Therapies pay a dividend?
Not currently.
Is BioRestorative Therapies a good stock to buy?
We do not give buy or sell advice. BioRestorative Therapies scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.